{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"14"}]}],"title":"Heart rate, Decrease to <60 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"17"}]}],"title":"Heart rate, Change to normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"}]}],"title":"Heart rate, Increase to >100 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"}]}],"title":"Systolic BP (mmHg) , increase to G3 or G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}],"title":"Diastolic BP (mmHg), increase to G3 or G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"39"}],"units":"Participants"}],"description":"Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury \\[mmHg\\]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to \\<60 bpm, change to normal or no change, or increase to \\>100 bpm are presented","groups":[{"description":"Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG000","title":"Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG001","title":"Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part D: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG003","title":"Part D: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"NUMBER","populationDescription":"ATP Population","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)","title":"Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure","type":"PRIMARY","unitOfMeasure":"Participants"}